Atomeg

KI-1107, marketed under the brand name Atomeg, is a fixed-dose combination (FDC) therapy developed by Kuhnil Pharmaceutical for the treatment of hyperlipidemia, specifically mixed dyslipidemia. It combines **atorvastatin**, a potent HMG-CoA reductase inhibitor (statin) that reduces LDL cholesterol and total cholesterol, with **omega-3-acid ethyl esters 90**, which primarily target the reduction of serum triglyceride levels. By integrating these two active ingredients into a single soft capsule, KI-1107 aims to provide a synergistic approach to managing complex lipid profiles while improving patient compliance. The drug was approved by the South Korean Ministry of Food and Drug Safety (MFDS) in 2020 and is commercially available in the South Korean market.

Brand names

Atomeg

Other names

atorvastatin + omega-3-acid ethyl esters